Beta-adrenergic receptor blocking drugs: tear lysozyme and immunological screening for adverse reaction.
Open Access
- 1 May 1977
- journal article
- research article
- Published by BMJ in British Journal of Ophthalmology
- Vol. 61 (5) , 354-359
- https://doi.org/10.1136/bjo.61.5.354
Abstract
Patients who had received long-term therapy with practolol and other beta-adrenergic receptor blocking drugs were examined ophthalmologically. Tear lysozyme concentration and serum autoantibodies (antinuclear antibodies, DNA-binding antibodies and intercellular cement substance antibodies) were measured. It was found that beta-adrenergic receptor blocking drugs may have a pharmacological effect on the lachrymal glands, but this was not associated with dry eyes or adverse reaction. Practolol was found to be capable of reducing tear lysozyme concentrations to very low levels, and this was initially associated with high titres of ICC antibody. No other drug tested produced these effects.This publication has 30 references indexed in Scilit:
- Tear fluid lysozyme concentration: guide to practolol toxicity.BMJ, 1975
- Ocular reaction to propranolol and resolution on continued treatment with a different beta-blocking drug.BMJ, 1975
- Antinuclear antibodies during procainamide treatment and drug acetylation.BMJ, 1975
- Oculocutaneous reaction to oxprenolol.BMJ, 1975
- Untoward effects associated with practolol administration: oculomucocutaneous syndrome.BMJ, 1975
- Letter: cutaneous and ocular reactions to practolol.BMJ, 1974
- Cutaneous and Ocular Reactions to PractololBMJ, 1974
- The Lysozyme Agar Diffusion Test in the Sicca SyndromeOphthalmologica, 1973
- SIGNIFICANCE OF ANTI-D.N.A. ANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUSThe Lancet, 1971
- Lupus-like syndrome induced by procainamideThe American Journal of Cardiology, 1967